Prevent Breast Cancer by Eating Mangoes!

Studies shows that Mango can prevent breast cancer, This conclusion was drawn after Researchers from Texas AgriLife Research Institute of Food has studied the 5 kinds of mango. Mangoes can be a great source of vitamin A, Sugar, protein, and other essential vitamins and minerals. 

Not all people know its role in health, it contains strong antioxidant. A study of Mango found that its anticancer properties can inhibit certain types of breast and colon cancer. Researchers studied the anti-oxidant extracted from mangoes called polyphenols which is  important in physiological activity material. It can increase the bodys metabolic rate and help the body burn more fat and calories.

It also contains carbohydrate, the protein, and lots of Vitamins. A team of researchers, from the University of Newcastle upon Tyne in England and Denmark, found the natural pesticide falcarinol reduced the risk of cancer. Carotene was ingested and then Converted into vitamin A. Vitamin A can maintain the normal human epithelial tissue structure and function, making it difficult violations of carcinogenic substances. Particularly suitable for the prevention and treatment of breast cancer.

It is  found out that mango does not kill normal cells, it is estimated that there will not harm the body. Mango on lung cancer, leukemia and prostate cancer have a certain effect, but the most common breast and colon cancer is very effective. Mango nutrient-rich, has the effect of anti-cancer, beautifying the skin, prevent high blood pressure, arteriosclerosis, prevent constipation, cough, clear the stomach.

Pain Killer for the Killer Cancer

In particular, the widely-used arthritis drug (also known as the COX-2 inhibitor celecoxib) has led to a 60% reduction of non-melanoma skin cancers – some of the most common cancers in the US with nearly 2 million diagnoses a year.

“For individuals who are at very high risk of skin cancer, this may be a method to reduce the number of new tumors they develop,” says study author Alice Pentland from the University of Rochester Medical Center, “despite the drug’s known side effects.” (These include ulcers and heart attack.)

In a clinical trial with 240 patients for over 11 months, the researchers found that celecoxib slowed or stopped actinic keratoses – flat, dry, scaly patches on sun-exposed areas like the arms, scalp, nose and back of the neck – from becoming full-fledged tumors.

Celecoxib didn’t prevent new actinic keratoses, but the number of non-melanoma skin cancers was lower in these patients than in control patients, all of whom started with 10 to 40 of these ‘premalignant precursors.’

There are no Food and Drug Administration (FDA)-approved agents for the prevention of non-melanoma skin cancers, although sunscreens are widely recommended for this purpose, according to study author Craig Elmetsof the University of Alabama at Birmingham. “However, even sunscreens are only modestly effective,” he adds. “The demonstration that celecoxib can prevent these common malignancies heralds an entirely new approach for the prevention of these common malignancies.”

In the future, a combination of protective measures, like sunscreens and hats, along with therapies like COX inhibitors may be used to decrease the incidence of skin cancer.

The direct treatment of these cancers is estimated to exceed $1.4 billion annually. And unlike many other malignancies, their incidences are increasing, especially in young people.

The study was published in the Journal of the National Cancer Institute and was jointly funded by Pfizer (the maker of Celebrex) and the National Cancer Institute at the National Institutes of Health.

H3 Biomedicine Launches To Discover And Develop Next Generation Cancer Treatments

H3 Biomedicine Inc. announced that it has launched research and development operations in Cambridge, Massachusetts. H3 Biomedicine will undertake a comprehensive approach to breakthrough oncology treatments based on two primary principles: 1) the genetics of patients' cancers can reveal drug targets tailored to their cancers and 2) the advances in modern chemistry enable the discovery of new classes of safe and effective drugs against these targets. Researchers worldwide are for the first time understanding the genetic basis of human cancers, and H3 Biomedicine will use that knowledge to generate new cancer treatments aimed at fulfilling the promise of personalized cancer medicine.

H3 Biomedicine will achieve its goals through a unique relationship with the pharmaceutical company Eisai Inc. Eisai has pledged up to $200 million in research funding to H3 Biomedicine, as well as additional support for the clinical development of H3 Biomedicine programs. In addition, H3 Biomedicine will benefit from access to many of Eisai's drug development capabilities, allowing H3 Biomedicine to focus on first-in-class drug discovery innovation.

H3 Biomedicine's scientific founders are renowned researchers Stuart L. Schreiber, PhD, and Todd R. Golub, MD, who will serve as academic advisors to the company. As founding members of the Broad Institute of Harvard and MIT, Drs. Schreiber and Golub have transformed the way medical research is done.

Dr. Schreiber's conceptual, experimental and leadership contributions have had a significant impact on chemistry, biology and medicine. Already, three new anti-cancer drugs that target cancer proteins discovered by Schreiber have been approved. In addition to his role at the Broad Institute, Dr. Schreiber serves as Morris Loeb Professor of Chemistry and Chemical Biology at Harvard University and an Investigator at the Howard Hughes Medical Institute.

Dr. Golub is a world leader in the genomic characterization of cancer. His work focuses on using the human genome to understand the biological and clinical challenges facing cancer medicine, and he has pioneered the use of genomic approaches to cancer biology and cancer drug discovery. In addition to his role at the Broad Institute, Dr. Golub is Charles A. Dana Investigator at the Dana-Farber Cancer Institute, Professor of Pediatrics at Harvard Medical School, and an Investigator at the Howard Hughes Medical Institute.

Unlike many biotech start-ups, H3 Biomedicine will have a unique relationship with Eisai that provides access to resources and capabilities of an established pharmaceutical company, while also encouraging and rewarding innovative and entrepreneurial spirit. Furthermore, the Eisai affiliation will enable H3 Biomedicine to take a longer-term view of its drug discovery activities than is typical of many venture-backed start-up companies. This model is thus intended to capture the best of both the biotech and large pharmaceutical company worlds.

Eisai's relationship with H3 Biomedicine also strengthens Eisai's commitment to advancing human health care through the development of medicines to treat unmet medical needs. "Our alliance with H3 Biomedicine represents a new approach to cancer drug discovery that holds enormous promise to help patients worldwide suffering from cancer," said Haruo Naito, President and CEO of Eisai Co., Ltd.

Kentaro Yoshimatsu, PhD, who serves as Chief Scientific Officer of Eisai Product Creation Systems, will take on the additional role of President of H3 Biomedicine. In this capacity, Dr. Yoshimatsu will ensure that H3 Biomedicine's unique business model is positioned for success while a search is conducted to identify a world-class leader to serve as Chief Scientific Officer of H3 Biomedicine.

In addition to its unique business model, the establishment of H3 Biomedicine represents a new paradigm for cancer drug discovery in which the ability to understand cancer genomes, coupled with advances in small-molecule science will serve as the foundation for creating the next generation of oncology treatments. H3 Biomedicine will follow a disciplined approach to drug discovery, relating the genetics of specific cancers to their unique vulnerabilities, and developing drugs that target those vulnerabilities. Using biomarkers to guide clinical development, H3 Biomedicine intends to enable the practice of personalized medicine for oncology patients. This biomarker-driven model for drug development is also expected to shorten clinical development timelines and reduce clinical trial costs.

According to the World Health Organization, cancer is the leading cause of death worldwide, accounting for 7.9 million deaths in 2007. Death from cancer is projected to rise, with an estimated 12 million deaths expected in 2030.

Marijuana's Anti-Cancer Properties

The active ingredient in marijuana appears to target cancerous brain cells for destruction while leaving healthy cells alone, according to a study conducted by researchers from the Complutense University in Madrid, and published in theJournal of Clinical Investigation.
Researchers first conducted an experiment in mice that had been engineered to carry three different grafts of human brain cancer. They injected the mice daily with the molecule tetrahydrocannabinol (THC) near the site of the tumors once each day. The chemical appeared to stimulate the cancerous cells to engage in a process known as autophagy, in which cells initiate their own breakdown.
"These results may help to design new cancer therapies based on the use of medicines containing the active principle of marijuana and/or in the activation of autophagy," researcher Guillermo Velasco said.
THC belongs to a class of chemicals known as cannabinoids, named after the cannabis (marijuana) plant in which they occur. It is the chemical responsible for the psychoactive effects of marijuana consumption.
In a followup experiment, the researchers extracted and analyzed brain tissue from two patients with an aggressive form of brain cancer known as "recurrent glioblastoma multiforme." The patients were treated with THC for either 26 or 30 days, then the researchers extracted and analyzed another sample.
After examining the brain tissue under an electron microscope, the researchers discovered that THC treatment resulted in death of cancerous cells but had no effect on healthy ones. The researchers were also able to discover the signaling pathway by which THC acts.
The research opens up the possibility that cannabinoid research could yield "a new family of potential antitumoral agents," the researchers wrote.
Glioblastoma multiforme is the most common and aggressive form of primary brain tumor. Without treatment, the average patient lives only three months after being diagnosed with the cancer. Treatment extends the average life expectancy after diagnosis by less than a year.